Acetic Acid

Acetic Acid

SCHEMBL1171378

CC(=O)O.CCCCCCC(O)CCO

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.63
FFAR4 Q5NUL3 1/20 0.63
GPR84 Q9NQS5 8/20 0.60
NFKB1 P19838 1/20 0.52
PSMD14 O00487 2/20 0.51
PLA2G1B P04054 2/20 0.51
MMP2 P08253 2/20 0.51
ATG4B Q9Y4P1 2/20 0.51
FAAH O00519 2/20 0.51
HSP90AA1 P07900 1/20 0.51
RAD52 P43351 1/20 0.51
ACE2 Q9BYF1 1/20 0.48
MAPT P10636 1/20 0.47
LCK P06239 1/20 0.47
PPARD Q03181 1/20 0.47
ZDHHC20 Q5W0Z9 1/20 0.47
ZDHHC2 Q9UIJ5 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL27652869 1.00 FFAR1 (0.63) FFAR1FFAR4GPR84NFKB1PSMD14
Acetic Acid SCHEMBL3205436 0.98 FFAR1 (0.60) FFAR1FFAR4GPR84NFKB1PSMD14
Bicarbonate SCHEMBL28829208 0.94 FFAR1 (0.66) FFAR1FFAR4GPR84NFKB1PSMD14
Acetic Acid SCHEMBL28392186 0.92 FFAR1 (0.73) FFAR1FFAR4GPR84NFKB1FAAH
Acetic Acid SCHEMBL29020019 0.92 FFAR1 (0.73) FFAR1FFAR4GPR84NFKB1FAAH
Acetic Acid SCHEMBL28707278 0.92 FFAR1 (0.73) FFAR1FFAR4GPR84NFKB1FAAH
Acetic Acid SCHEMBL4019504 0.92 FFAR1 (0.73) FFAR1FFAR4GPR84NFKB1FAAH
Acetamide SCHEMBL8064165 0.90 FFAR1 (0.56) FFAR1FFAR4GPR84NFKB1PSMD14
Acetic Acid SCHEMBL672595 0.90 FFAR1 (0.70) FFAR1FFAR4GPR84NFKB1FAAH
SCHEMBL23188459 0.89 FFAR4 (0.57) FFAR1FFAR4GPR84NFKB1PSMD14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400468-A1 Bionutritional Compositions for Plants and Soils ENVIROKURE, INCORPORATED (US) 2024-12-05 US claimed
EP-4377280-A1 BIONUTRITIONAL COMPOSITIONS FOR PLANTS AND SOILS Envirokure Incorporated (US) 2024-06-05 EP claimed
EP-4257663-A1 FOOD CONTACT SURFACE SANITIZING LIQUID The Procter & Gamble Company (US) 2023-10-11 EP claimed
WO-2023009636-A1 BIONUTRITIONAL COMPOSITIONS FOR PLANTS AND SOILS ENVIROKURE, INCORPORATED (US) 2023-02-02 WO claimed
CN-113201138-B Transparent light-curable high-refractive-index mercapto silicone oil and preparation method thereof 惠州学院 2022-11-22 CN claimed
CN-113201138-A Transparent light-curable high-refractive-index mercapto silicone oil and preparation method thereof 惠州学院 2021-08-03 CN claimed
WO-2018145219-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING SERANI MOSTAZAL JORGE (CL) 2018-08-16 WO claimed
US-9981937-B2 Orthoformic acid esters as pro-fragrances HENKEL AG & CO. KGAA (DE) 2018-05-29 US claimed
US-20170349565-A1 ORTHOFORMIC ACID ESTERS AS PRO-FRAGRANCES HENKEL AG & CO. KGAA (DE) 2017-12-07 US claimed
CN-101316922-B Stable odorant systems THE PROCTER & GAMBLE CO. (US) 2011-12-14 CN claimed
EP-1716159-B1 BICYCLIC SILOXANE COMPOSITIONS FOR THE RELEASE OF ACTIVE INGREDIENTS MOMENTIVE PERFORMANCE MAT INC (US) 2011-07-13 EP claimed
US-7579495-B2 Active-releasing cyclic siloxanes MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2009-08-25 US claimed
US-7576170-B2 Cyclic siloxane compositions for the release of active ingredients MOMENTIVE PERFORMANCE MATERIALS (US) 2009-08-18 US claimed
EP-1697386-B1 ACTIVE INGREDIENT-RELEASING CYCLIC SILOXANES GEN ELECTRIC (US) 2007-10-10 EP claimed
EP-1716159-A2 CYCLIC SILOXANE COMPOSITIONS FOR THE RELEASE OF ACTIVE INGREDIENTS General Electronic Company (US) 2006-11-02 EP claimed
EP-1697386-A1 ACTIVE INGREDIENT-RELEASING CYCLIC SILOXANES General Electric Company A Corporation of the State of New York (US) 2006-09-06 EP claimed
WO-2005066187-A1 ACTIVE INGREDIENT-RELEASING CYCLIC SILOXANES GENERAL ELECTRIC COMPANY (US) 2005-07-21 WO claimed
WO-2005066186-A2 CYCLIC SILOXANE COMPOSITIONS FOR THE RELEASE OF ACTIVE INGREDIENTS GENERAL ELECTRIC COMPANY (US) 2005-07-21 WO claimed
US-20050136021-A1 Active-releasing cyclic siloxanes MOMENTIVE PERFORMANCE MATERIALS INC. 2005-06-23 US claimed
US-20050136022-A1 Cyclic siloxane compositions for the release of active ingredients MOMENTIVE PERFORMANCE MATERIALS INC. 2005-06-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349565-A1 ORTHOFORMIC ACID ESTERS AS PRO-FRAGRANCES FAAH, NISCH, ELOVL6 FFAR1 9/4885FFAR4 39/4885GPR84 356/4885
US-20050136022-A1 Cyclic siloxane compositions for the release of active ingredients F9, RPL39, ECPAS FFAR1 320/4885FFAR4 1009/4885GPR84 651/4885
US-20050136021-A1 Active-releasing cyclic siloxanes F9, RPL39, ALDH16A1 FFAR1 179/4885FFAR4 702/4885GPR84 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.